Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novartis AG (NYSE:NVS)

74.43
Delayed Data
As of 4:02pm ET
 +0.24 / +0.32%
Today’s Change
66.93
Today|||52-Week Range
83.58
+2.18%
Year-to-Date
AVEO (AVEO) Reports Narrower-than-Expected Loss in Q4
5:25pm / Zacks.com - Paid Partner Content
Novartis (NVS) Announces Positive Data on Heart Failure Drug
Mar 20 / Zacks.com - Paid Partner Content
Novartis' Acute Heart Failure Drug Fails in Late-Stage Study
Mar 22 / Zacks.com - Paid Partner Content
Conatus Pharma (CNAT) Incurs Wider-than-Expected Loss in Q4
Mar 16 / Zacks.com - Paid Partner Content
Array BioPharma's NDA for Cancer Drug Withdrawn; Shares Down
Mar 22 / Zacks.com - Paid Partner Content
Glaxo Files for Label Expansion of Influenza Vaccine in US
Mar 16 / Zacks.com - Paid Partner Content
Novartis Shares Extend Declines After Serelaxin Fails Global Phase III Trials
Mar 22 / TheStreet.com - Paid Partner Content
Novartis Takes Aim at Pfizer in Breast Cancer
Mar 14 / MotleyFool.com - Paid Partner Content
Security Asset Management Buys TransDigm Group, Intel, Novartis AG, Sells Cerner, Tim...
Mar 21 / GuruFocus News - Paid Partner Content
Novartis Breast Cancer Drug OK'd by FDA as First-line Therapy
Mar 14 / Zacks.com - Paid Partner Content
Does Novartis (NVS) Stock Make a Good Value Pick?
Mar 21 / Zacks.com - Paid Partner Content
Aerie Resubmits Rhopressa NDA, Roclatan Gains Traction
Mar 13 / Zacks.com - Paid Partner Content
6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017
Mar 21 / Zacks.com - Paid Partner Content
How Incyte Stock Became a Bull Market Star for Biotech Investors
Mar 10 / Zacks.com - Paid Partner Content
Lilly's Breast Cancer Combo Drug Phase III Results Positive
Mar 21 / Zacks.com - Paid Partner Content
5 Reasons Celgene Will Be a Top Biotech Stock for the Next Decade
Mar 09 / MotleyFool.com - Paid Partner Content